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ABSTRACT 
In an attempt prasugrel increase in the overall use of this medication comparing to the anti thrombolytics like heparin and warfarin, 
with less patients complaints includes side effects a significant portion of patients receiving the medication for off label indications. 
More importantly, this agent is used in a substantial number of patients with known contraindications. Prasugrel are more intense 
platelet inhibition confirmed by the observation of highest percentage of minor or moderate bleeding among patients taking 
prasugrel, although there was no significant increase in the rate of severe, major, or life-threatening bleeding. 
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INTRODUCTION 
Prasugrel is a recently approved drug under the class of 
thienopyridine for used in the patients with acute 
coronary syndromes undergoing percutaneous coronary 
intervention. In an early invasive strategy has become 
the standard of care for patients having with non–ST-
segment elevation of myocardial infarction (NSTEMI). 
Atherosclerotic plaque can also disruption erosion with 
superimposed thrombus is the underlying etiology of 
most cases of NSTEMI. Consequently, many of the 
patients with NSTEMI undergo percutaneous coronary 
intervention (PCI) and are treated with coronary stenting 
during the index catheterization procedure. 
Approximately one-third of patients are typically triaged 
after diagnostic angiography to cardiac procedure or 
treated medically. Besides early catheterization, 
anticoagulant/antiplatelet therapies represent the 
cornerstone of pharmacological strategy for NSTEMI. 
The role of dual antiplatelet therapy (aspirin plus a 
P2Y12 inhibitor) has been shown to be critical not only 
as immediate treatment of the NSTEMI episode but also 
as maintenance therapy to prevent stent thrombosis and 
major adverse cardiovascular events in the long term. 
Thus, it is rather remarkable that the best timing for the 
initiation of P2Y12 inhibitors in patients with NSTEMI 
has not been clearly established. Clinical guidelines (the 
2012 American College of Cardiology 
Foundation/American Heart Association Focused 
Update and 2011 European Society of Cardiology 
guidelines) recommend the initiation of P2Y12 
inhibitors “on presentation; as soon as possible” (i.e., 
before catheterization) on the basis of clinical evidence 
showing that “on admission” initiation of P2Y12 
inhibitors with clopidogrel was superior to no 
administration of P2Y12 inhibitors. This appeared to be 
a reasonable expert consensus given the delayed onset of 
peak antiplatelet activity with the loading dose of 
clopidogrel. Until the publication of the ACCOAST (A 
Comparison of prasugrel at the time of percutaneous 
Coronary intervention or as pre-treatment at the time of 
diagnosis in patients with non-ST segment elevation 
myocardial infarction) trial, no study had ever compared 
different timings of P2Y12 initiation in patients with 
NSTEMI, making it a landmark trial. The ACCOAST 
trial randomized 4,033 patients with NSTEMI to pre-
treatment with prasugrel (a loading dose of prasugrel 2 
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to 48 h before catheterization) or no pre-treatment with 
prasugrel (a loading dose of prasugrel after initial 
angiography). The primary endpoint (composite of 
cardiovascular death, myocardial infarction, stroke, 
urgent revascularization, or glycoprotein IIb/IIIa 
inhibitor bailout through day 7) was not different 
between groups. This result implied that a similar 
clinical effect with a fast-acting agent (onset within 30 
min) can be achieved even if it is given after definition 
of the coronary anatomy when planning for PCI, thus 
avoiding unnecessary treatment with this agent for 
patients suitable for cardiac surgery procedure or 
medical therapy alone. The rate of bleeding events (both 
coronary artery bypass graft [CABG] related and non-
CABG related) at 7 and 30 days was significantly higher 
in the prasugrel pre-treatment group than in the no 
prasugrel pre-treatment group.  
MECHANISM OF ACTION 
prasugrel inhibits the platelet activation and aggregation 
through Irreversible inhibition of the platelet P2Y12 
Adenosine phosphate (ADP) receptor. It is a prodrug it 
is rapidly metabolized to pharmacology active 
compound 
CONCLUSION AND DISCUSSION 
We are concluding that the use of prasugrel and trends in 
its clinical prescribing practices since drug approval. 
There are some investigational studies conclude that the 
prasugrel  increase in the overall use of this medication 
comparing to the anti thrombolytics like heparin and 
warfarin, with less patients complaints includes side 
effects a significant portion of patients receiving the 
medication for off label indications. More importantly, 
this agent is used in a substantial number of patients 
with known contraindications. There are some 
investigations shows prasugrel are more intense platelet 
inhibition confirmed by the observation of highest 
percentage of minor or moderate bleeding among 
patients taking prasugrel, although there was no 
significant increase in the rate of severe, major, or life-
threatening bleeding. 
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